CTLA4 and mesothelioma: Prior to Checkmate-743, several earlier trials had tested CTLA4, PD-1 and PD-L1 antagonists for relapsed mesothelioma, with adoption of dual immune checkpoint blockade into treatment guidelines [2–5].